Skip to main content
Erschienen in: Tumor Biology 1/2016

12.08.2015 | Original Article

Knockdown of Rad9A enhanced DNA damage induced by trichostatin A in esophageal cancer cells

verfasst von: Xueli Pang, Gang He, Chao Luo, Yan Wang, Bo Zhang

Erschienen in: Tumor Biology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Histone deacetylase (HDAC) inhibitors have recently emerged as a new class of anticancer agents. As a classical HDAC inhibitor, trichostatin A (TSA) has been shown to possess many anticancer activities such as induction of cell cycle arrest, promotion of cell death, and enhancement of radiosensitity. In our previous work, we found that TSA treatment induced Rad9 gene expression, which suggested that Rad9 might play a role in TSA-induced biological effects. As Rad9 is involved in maintaining genomic integrity, we further analyzed the DNA damage induced by TSA and combined with Rad9 knockdown in esophageal cancer cells (ESCCs). Our results showed that TSA treatment alone induced significantly DNA damage in ESCC cells. Simultaneously, TSA also induced Rad9 gene expression both at transcriptional and translational levels in EC109 cells, but not in KYSE150 cells. Further, the induction of Rad9 by TSA was accompanied with increased level of histone H3K9 acetylation in Rad9 promoter region. To understand the role of Rad9 in TSA-induced DNA damage, Rad9 gene expression was efficiently knocked down by small interfering RNA (siRNA), which led to enhanced DNA damage and cell death induced by TSA. Our data suggested that Rad9 plays an important role in DNA damage, which is related to the biological effects of TSA.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–91.CrossRefPubMed Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–91.CrossRefPubMed
3.
Zurück zum Zitat Sachweh MC, Drummond CJ, Higgins M, Campbell J, Laín S. Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression. Cell Death Dis. 2013;4, e533.CrossRefPubMedPubMedCentral Sachweh MC, Drummond CJ, Higgins M, Campbell J, Laín S. Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression. Cell Death Dis. 2013;4, e533.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Chatterjee N, Wang WL, Conklin T, Chittur S, Tenniswood M. Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells. Cancer Biol Ther. 2013;14(7):658–71.CrossRefPubMedPubMedCentral Chatterjee N, Wang WL, Conklin T, Chittur S, Tenniswood M. Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells. Cancer Biol Ther. 2013;14(7):658–71.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Yang H, Zhong Y, Xie H, Lai X, Xu M, Nie Y, et al. Induction of the liver cancer-down-regulated long noncoding RNA uc002mbe.2 mediates trichostatin- induced apoptosis of liver cancer cells. Biochem Pharmacol. 2013;85(12):1761–9.CrossRefPubMedPubMedCentral Yang H, Zhong Y, Xie H, Lai X, Xu M, Nie Y, et al. Induction of the liver cancer-down-regulated long noncoding RNA uc002mbe.2 mediates trichostatin- induced apoptosis of liver cancer cells. Biochem Pharmacol. 2013;85(12):1761–9.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Felisbino MB, Gatti MS, Mello ML. Changes in chromatin structure in NIH 3T3 cells induced by valproic acid and trichostatin A. J Cell Biochem. 2014;115(11):1937–47.PubMed Felisbino MB, Gatti MS, Mello ML. Changes in chromatin structure in NIH 3T3 cells induced by valproic acid and trichostatin A. J Cell Biochem. 2014;115(11):1937–47.PubMed
7.
Zurück zum Zitat Sharma S, Taliyan R, Ramagiri S. Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice. J Mol Neurosci. 2014 Nov 14. Sharma S, Taliyan R, Ramagiri S. Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice. J Mol Neurosci. 2014 Nov 14.
8.
Zurück zum Zitat Ye Q, Li Y, Jiang H, Xiong J, Xu J, Qin H, et al. Prevention of pulmonary fibrosis via trichostatin A (TSA) in bleomycin induced rats. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(3):219–26.PubMed Ye Q, Li Y, Jiang H, Xiong J, Xu J, Qin H, et al. Prevention of pulmonary fibrosis via trichostatin A (TSA) in bleomycin induced rats. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(3):219–26.PubMed
9.
Zurück zum Zitat He G, Wang Y, Pang X, Zhang B. Inhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation. Tumour Biol. 2014;35(2):1003–11.CrossRefPubMed He G, Wang Y, Pang X, Zhang B. Inhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation. Tumour Biol. 2014;35(2):1003–11.CrossRefPubMed
10.
Zurück zum Zitat Barazzuol L, Jeynes JC, Merchant MJ, Wéra AC, Barry M, Kirkby KJ, et al. Radiosensitisation of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays. Int J Radiat Biol. 2014;21(1):1–19. Barazzuol L, Jeynes JC, Merchant MJ, Wéra AC, Barry M, Kirkby KJ, et al. Radiosensitisation of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays. Int J Radiat Biol. 2014;21(1):1–19.
11.
Zurück zum Zitat Xiao W, Graham PH, Hao J, Chang L, Ni J, Power CA, et al. Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PLoS One. 2013;8(8), e74253.CrossRefPubMedPubMedCentral Xiao W, Graham PH, Hao J, Chang L, Ni J, Power CA, et al. Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PLoS One. 2013;8(8), e74253.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Di Bernardo G, Alessio N, Dell’Aversana C, Casale F, Teti D, Cipollaro M, et al. Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol. 2010;225(2):537–44.CrossRefPubMed Di Bernardo G, Alessio N, Dell’Aversana C, Casale F, Teti D, Cipollaro M, et al. Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol. 2010;225(2):537–44.CrossRefPubMed
13.
Zurück zum Zitat Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 2006;66(23):11298–304.CrossRefPubMed Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 2006;66(23):11298–304.CrossRefPubMed
14.
Zurück zum Zitat Zhang Y, Adachi M, Zou H, Hareyama M, Imai K, Shinomura Y. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int J Radiat Oncol Biol Phys. 2006;65(3):859–66.CrossRefPubMed Zhang Y, Adachi M, Zou H, Hareyama M, Imai K, Shinomura Y. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int J Radiat Oncol Biol Phys. 2006;65(3):859–66.CrossRefPubMed
15.
Zurück zum Zitat Yaneva M, Li H, Marple T, Hasty P. Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor. Nucleic Acids Res. 2005;33(16):5320–30.CrossRefPubMedPubMedCentral Yaneva M, Li H, Marple T, Hasty P. Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor. Nucleic Acids Res. 2005;33(16):5320–30.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Liu Y, He G, Wang Y, Guan X, Pang X, Zhang B. MCM-2 is a therapeutic target of trichostatin A in colon cancer cells. Toxicol Lett. 2013;221(1):23–30.CrossRefPubMed Liu Y, He G, Wang Y, Guan X, Pang X, Zhang B. MCM-2 is a therapeutic target of trichostatin A in colon cancer cells. Toxicol Lett. 2013;221(1):23–30.CrossRefPubMed
17.
Zurück zum Zitat Wang G, Tong X, Weng S, Zhou H. Multiple phosphorylation of Rad9 by CDK is required for DNA damage checkpoint activation. Cell Cycle. 2012;11(20):3792–800.CrossRefPubMedPubMedCentral Wang G, Tong X, Weng S, Zhou H. Multiple phosphorylation of Rad9 by CDK is required for DNA damage checkpoint activation. Cell Cycle. 2012;11(20):3792–800.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat He W, Ma X, Yang X, Zhao Y, Qiu J, Hang H. A role for the arginine methylation of Rad9 in checkpoint control and cellular sensitivity to DNA damage. Nucleic Acids Res. 2011;39(11):4719–27.CrossRefPubMedPubMedCentral He W, Ma X, Yang X, Zhao Y, Qiu J, Hang H. A role for the arginine methylation of Rad9 in checkpoint control and cellular sensitivity to DNA damage. Nucleic Acids Res. 2011;39(11):4719–27.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Hopkins KM, Auerbach W, Wang XY, Hande MP, Hang H, Wolgemuth DJ, et al. Deletion of mouse rad9 causes abnormal cellular responses to DNA damage, genomic instability, and embryonic lethality. Mol Cell Biol. 2004;24(16):7235–48.CrossRefPubMedPubMedCentral Hopkins KM, Auerbach W, Wang XY, Hande MP, Hang H, Wolgemuth DJ, et al. Deletion of mouse rad9 causes abnormal cellular responses to DNA damage, genomic instability, and embryonic lethality. Mol Cell Biol. 2004;24(16):7235–48.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Yin Y, Zhu A, Jin YJ, Liu YX, Zhang X, Hopkins KM, et al. Human RAD9 checkpoint control/proapoptotic protein can activate transcription of p21. Proc Natl Acad Sci U S A. 2004;101(24):8864–9.CrossRefPubMedPubMedCentral Yin Y, Zhu A, Jin YJ, Liu YX, Zhang X, Hopkins KM, et al. Human RAD9 checkpoint control/proapoptotic protein can activate transcription of p21. Proc Natl Acad Sci U S A. 2004;101(24):8864–9.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Li ZH, Zhang XB, Han XQ, Feng CR, Wang FS, Wang PG, et al. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer. Oncol Rep. 2013;30(1):499–505.PubMed Li ZH, Zhang XB, Han XQ, Feng CR, Wang FS, Wang PG, et al. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer. Oncol Rep. 2013;30(1):499–505.PubMed
23.
Zurück zum Zitat Karagiannis TC, Harikrishnan KN, El-Osta A. Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments. Oncogene. 2007;26(27):3963–71.CrossRefPubMed Karagiannis TC, Harikrishnan KN, El-Osta A. Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments. Oncogene. 2007;26(27):3963–71.CrossRefPubMed
24.
Zurück zum Zitat Zhang B, Wang Y, Pang X. Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression. Med Oncol. 2012;29(1):340–8.CrossRefPubMed Zhang B, Wang Y, Pang X. Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression. Med Oncol. 2012;29(1):340–8.CrossRefPubMed
25.
Zurück zum Zitat Jang SM, Kang EJ, Kim JW, Kim CH, An JH, Choi KH. Transcription factor Sox4 is required for PUMA-mediated apoptosis induced by histone deacetylase inhibitor, TSA. Biochem Biophys Res Commun. 2013;438(2):445–51.CrossRefPubMed Jang SM, Kang EJ, Kim JW, Kim CH, An JH, Choi KH. Transcription factor Sox4 is required for PUMA-mediated apoptosis induced by histone deacetylase inhibitor, TSA. Biochem Biophys Res Commun. 2013;438(2):445–51.CrossRefPubMed
26.
Zurück zum Zitat Zhao ZN, Bai JX, Zhou Q, Yan B, Qin WW, Jia LT, et al. TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. PLoS One. 2012;7(9), e45133.CrossRefPubMedPubMedCentral Zhao ZN, Bai JX, Zhou Q, Yan B, Qin WW, Jia LT, et al. TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. PLoS One. 2012;7(9), e45133.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Yao J, Qian CJ, Ye B, Zhang X, Liang Y. ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-κB-dependent and Notch-independent mechanism. Life Sci. 2012;91(5–6):186–93.CrossRefPubMed Yao J, Qian CJ, Ye B, Zhang X, Liang Y. ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-κB-dependent and Notch-independent mechanism. Life Sci. 2012;91(5–6):186–93.CrossRefPubMed
28.
Zurück zum Zitat Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858–68.CrossRefPubMed Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858–68.CrossRefPubMed
29.
Zurück zum Zitat Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol. 2014;15(11):703–8.CrossRefPubMed Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol. 2014;15(11):703–8.CrossRefPubMed
30.
Zurück zum Zitat Carafa V, Nebbioso A, Altucci L. Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat Anticancer Drug Discov. 2011;6(1):131–45.CrossRefPubMed Carafa V, Nebbioso A, Altucci L. Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat Anticancer Drug Discov. 2011;6(1):131–45.CrossRefPubMed
31.
Zurück zum Zitat Ho AS, Turcan S, Chan TA. Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. Onco Targets Ther. 2013;6:223–32.PubMedPubMedCentral Ho AS, Turcan S, Chan TA. Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. Onco Targets Ther. 2013;6:223–32.PubMedPubMedCentral
32.
Zurück zum Zitat Smith S, Fox J, Mejia M, Ruangpradit W, Saberi A, Kim S, et al. Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. PLoS One. 2014;9(1), e87203.CrossRefPubMedPubMedCentral Smith S, Fox J, Mejia M, Ruangpradit W, Saberi A, Kim S, et al. Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. PLoS One. 2014;9(1), e87203.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Ververis K, Rodd AL, Tang MM, El-Osta A, Karagiannis TC. Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes. Cell Mol Life Sci. 2011;68(24):4101–14.CrossRefPubMed Ververis K, Rodd AL, Tang MM, El-Osta A, Karagiannis TC. Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes. Cell Mol Life Sci. 2011;68(24):4101–14.CrossRefPubMed
34.
Zurück zum Zitat Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M. Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res. 2007;168(1):115–24.CrossRefPubMed Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M. Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res. 2007;168(1):115–24.CrossRefPubMed
35.
Zurück zum Zitat Lee MC, Lopez-Diaz FJ, Khan SY, Tariq MA, Dayn Y, Vaske CJ, et al. Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. Proc Natl Acad Sci U S A. 2014;111(44):E4726–35.CrossRefPubMedPubMedCentral Lee MC, Lopez-Diaz FJ, Khan SY, Tariq MA, Dayn Y, Vaske CJ, et al. Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. Proc Natl Acad Sci U S A. 2014;111(44):E4726–35.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Broustas CG, Lieberman HB. RAD9 enhances radioresistance of human prostate cancer cells through regulation of ITGB1 protein levels. Prostate. 2014;74(14):1359–70.CrossRefPubMedPubMedCentral Broustas CG, Lieberman HB. RAD9 enhances radioresistance of human prostate cancer cells through regulation of ITGB1 protein levels. Prostate. 2014;74(14):1359–70.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Dong Q, Sharma S, Liu H, Chen L, Gu B, Sun X, et al. HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression. Toxicol Lett. 2014;224(1):121–9.CrossRefPubMed Dong Q, Sharma S, Liu H, Chen L, Gu B, Sun X, et al. HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression. Toxicol Lett. 2014;224(1):121–9.CrossRefPubMed
38.
Zurück zum Zitat Cai RL, Yan-Neale Y, Cueto MA, Xu H, Cohen D. HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G2/M checkpoint Rad proteins. J Biol Chem. 2000;275(36):27909–16.PubMed Cai RL, Yan-Neale Y, Cueto MA, Xu H, Cohen D. HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G2/M checkpoint Rad proteins. J Biol Chem. 2000;275(36):27909–16.PubMed
Metadaten
Titel
Knockdown of Rad9A enhanced DNA damage induced by trichostatin A in esophageal cancer cells
verfasst von
Xueli Pang
Gang He
Chao Luo
Yan Wang
Bo Zhang
Publikationsdatum
12.08.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3879-z

Weitere Artikel der Ausgabe 1/2016

Tumor Biology 1/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.